Linezolid and Clindamycin Combination Therapy
Introduction to Combination Therapy
- The Infectious Diseases Society of America recommends that for necrotizing fasciitis caused by Group A Streptococcus, clindamycin plus penicillin is the recommended regimen due to clindamycin's ability to suppress streptococcal toxin and cytokine production 1
- If MRSA coverage is also needed empirically, linezolid could theoretically replace vancomycin while maintaining clindamycin for its antitoxin effects 1
Pharmacologic Considerations
- Clindamycin or linezolid in combination with vancomycin can be antagonistic in vitro, and vancomycin alone was more effective than vancomycin plus linezolid in a rabbit endocarditis model 2
- Both linezolid and clindamycin are protein synthesis inhibitors with overlapping mechanisms, making their combination redundant for bacterial killing 2
- Using both simultaneously provides no additional benefit for toxin suppression beyond either agent alone 2
Guideline-Recommended Alternatives
- The Infectious Diseases Society of America recommends linezolid 600 mg PO/IV twice daily (A-I recommendation) for MRSA coverage in skin and soft tissue infections 3, 4
- The Infectious Diseases Society of America also recommends clindamycin 600 mg IV/PO three times daily (A-III recommendation) for MRSA coverage in skin and soft tissue infections, but only if local resistance rates are low (<10%) 3, 4
- Linezolid alone covers both streptococci and MRSA (A-II recommendation), eliminating the need for combination therapy 3, 4
Clinical Decision-Making
- For confirmed Group A Streptococcus with necrotizing infection, the Infectious Diseases Society of America recommends using penicillin plus clindamycin 1
- For confirmed MRSA, the Infectious Diseases Society of America recommends using linezolid or clindamycin (not both) based on susceptibility 3, 4